Najat Khan - 01 Aug 2024 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role: Chief R&D Commercial Officer, Director
Signature: /s/ Jonathan Golightly, attorney-in-fact
Issuer symbol: RXRX
Transactions as of: 01 Aug 2024
Net transactions value: $0
Form type: 4
Filing time: 05 Aug 2024, 17:12:25 UTC
Previous filing: 25 Apr 2024
Next filing: 05 Feb 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RXRX	Class A Common Stock	Award	$0	+496,972		$0.000000	496,972	01 Aug 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RXRX	Stock Option (Right to Buy)	Award	$0	+993,944		$0.000000	993,944	01 Aug 2024	Class A Common Stock	993,944	$7.34	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This RSU vests as to one fourth (1/4th) of the units subject to the RSU on August 15, 2025 and one sixteenth (1/16th) every three months thereafter subject to Reporting Person's continued service to the Issuer through each such vesting date.
F2	This option vests as to one fourth (1/4th) of the shares subject to the option on July 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter subject to Reporting Person's continued service to the Issuer through each such vesting date.